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Abstract
Background: Controversies existed surrounding the use of hematocrit to guide early
fluid therapy in acute pancreatitis (AP). The association between hematocrit, early
fluid therapy, and clinical outcomes in ward AP patients needs to be investigated.
Methods: Data from prospectively maintained AP database and retrospectively col-
lected details of fluid therapy were analyzed. Patients were stratified into three groups:
Group 1, hematocrit < 44% both at admission and at 24 h thereafter; Group 2: regard-
less of admission level, hematocrit increased and >44% at 24 h; Group 3: hematocrit
>44% on admission and decreased thereafter during first 24 h. “Early” means first
24 h after admission. Baseline characteristics, early fluid rates, and clinical outcomes
of the three groups were compared.
Results: Among the 628 patients, Group 3 had a higher hematocrit level, greater
baseline predicted severity, faster fluid rate, and more fluid volume in the first 24 h
compared with Group 1 or 2. Group 3 had an increased risk for persistent organ fail-
ure (POF; odds ratio 2, 95% confidence interval [1.1–3.8], P = 0.03) compared with
Group 1 after adjusting for difference in baseline clinical severity scores, there was no
difference between Group 2 and Group 3 or Group 1. Multivariate regression analyses
revealed that hemoconcentration and early faster fluid rate were risk factors for POF
and mortality (both P < 0.05).
Conclusions: Hemoconcentration is associated with faster fluid rate and POF in ward
AP patients. Randomized trials comparing standardized early fast and slow fluid man-
agement is warranted.
doi:10.1002/jgh3.12320
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Introduction
Acute pancreatitis (AP) is one of the most common digestive
diseases affecting 34 cases per 100 000 person/year.1,2 Its
severe form, defined as developing persistent organ failure (POF)
or multiple organ failure (MOF), carries a mortality of 36–50%.3
Currently, there is no effective pharmacological therapy for AP4
and Practice Guidelines support fluid therapy using crystalloids as
the mainstay treatment for its early management.5,6
Recent studies related to early fluid therapy in AP focused
on the population who admitted primarily in Emergency Depart-
ment (ED) without any fluid therapy before and did not progress
to organ failure on admission,7–9 or those who directly admitted
to Intensive Care Unit (ICU). However, the population who have
completed emergency care, but do not merit the criteria of ICU
monitoring actually represent the majority of hospitalized
patients. As far as we know, the fluid characterization of these
patients (i.e. patients who admitted in ward after initial fluid
management) has been rarely studied.
Hypovolemia caused by AP is the origin of the increase in
hematocrit. Early studies have linked increased admission serum
hematocrit level and its subsequent rise with acute necrotic collec-
tion (ANC) and organ failure.10–12 In a recent prospective multicen-
ter study, admission hematocrit more than 44% has been shown to
outperform other biomarkers in predicting POF and ANC.13 Fur-
ther, hematocrit is one of the mostly widely used, routinely obtained
and simple laboratory biomarkers to guide early fluid resuscitation
for AP patients but there is still controversy.6,14
In the study, we investigated the feature of early fluid man-
agement of AP patients from the largest AP tertiary center in
China.15,16 The association between hemoconcentration, early fluid
therapy, and outcomes in general ward AP patients were delineated
(Fig. 1a). We hypothesized that hemoconcentration would be asso-
ciated with early faster fluid rate and increased risk of POF in ward
AP patients, with the aim to promote randomized trials comparing
standardized early fast and slow fluid therapy strategies.
Materials and methods
Study design, ethics, and patients. This was a single-
center study following the STROBE guidelines for observational
studies in West China Hospital of Sichuan University. Our hospi-
tal is a 4900-bed national center (180 ICU beds) for the diagnosis
and treatment of complex and critical diseases in Western China.
The study protocol was approved by the Institutional Review
Board (No. 247) of our hospital, informed consent was waived
due anonymized use of data. All AP patients were consecutively
admitted to the Department of Integrated Traditional Chinese and
Western Medicine (Sichuan Provincial Pancreatitis Centre) of
our institution between first January 2016 and 31th August 2017
and relevant data were maintained in our prospective AP data-
base. Data of fluid management details were retrospectively
collected.
Inclusion and exclusion criteria. AP was diagnosed as
per the revised Atlanta classification3 and patients were included
if they had less than 48 h of symptom, regardless of whether they
were from a primary or referral status. Exclusion criteria were in
Supplementary Materials and Methods.
Fluid management. Patients were first assessed in the ED
to confirm the diagnosis of AP, regardless of whether they were
primarily admitted or referred. They were routinely given normal
saline fluid therapy. When transferred to designated general
wards, patients were continued on intravenous crystalloids (nor-
mal saline or Ringer’s lactate solution) at 1–5 mL/kg/h for the
first 24 h according to severity of patients and hydration status.
Patients routinely receive maintenance fluid rates unless shock
was present (bolus fluid [10–20 mL/kg/h was given within
30–45 min]) when shock happened.17
Indications for admission to High Dependency Unit
(HDU) included the need for noninvasive ventilation. Indications
for admission to ICU included invasive ventilation or renal
replacement therapy.
Definitions and patient groups. “Early” refers to the
first 24 h after general ward admission and starting fluid therapy.
Hematocrit was measured upon ward admission and around the
next 24 h. Hemoconcentration was defined as a serum hematocrit
>44%.10,12,13 The patients were stratified into three groups based
on their hematocrit profiles within the first 24 h since ward
admission: Group 1: hematocrit <44% both on admission and at
24 h thereafter; Group 2: regardless of inclusion level, hematocrit
increased and > 44% at 24 h; Group 3: hematocrit >44% on
admission and decreased thereafter during first 24 h. The primary
clinical outcome was development of POF.18 Other outcomes
included MOF, HDU/ICU admission, respiratory support, local
complications, and overall mortality. Definitions of other vari-
ables are listed in Supplementary Materials and Methods.
Statistical analysis. Categorical data are expressed as num-
ber and percentage and compared by χ2 test (or Fisher’s exact
test) or proportional trend test (ordered multiple groups). Contin-
uous data are presented as median and interquartile range (IQR)
and compared using Mann–Whitney U test (two groups) or
Kruskal–Wallis H test (three groups) because of the skewed dis-
tribution. Baseline variables with or without clinical severity
score on admission are compared between designated groups
using univariate analysis, these covariates with P value < 0.2 are
further fitted into multivariate logistic regression (MLR) analyses
for categorical clinical outcomes and expressed as odds ratio
(OR) with 95% confidence interval (CI). A two-sided P < 0.05
was considered statistically significant. Statistical analyses were
performed using SPSS 21.0 (IBM, Armonk, New York, USA).
Results
Baseline characteristics of overall included
patients. Patient selection flow chart is shown in Figure 1b. Six
hundred and twenty eight patients were included: median age 45 years
and 68% males. Hypertriglyceridemia (40.0%) was the leading etiol-
ogy, followed by biliary (23.2%) and heavy alcohol use (7.8%). The
baseline characteristics and clinical outcomes stratified by Revised
Atlanta Classification3 are summarized (Table S1) and there were
223 (35.5%), 274 (43.6%), and 131 (20.9%) patients graded as mild,
moderately severe, and severe category, respectively.
The clinical outcomes are demonstrated (Table S1). The
median symptom onset time was 24 h. The proportion of patients
that developed persistent OF on day 1, 2, 3 and ≥4 was 64.2%,
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29.8%, 2%, and 5% patients respectively (Fig. S1). There were
124 (19.7%) respiratory, 14 (2.2%) circulatory and 22 (3.5%)
renal persistent OF，23 (3.7%) patients developed MOF. The
number of patients that required HDU/ICU admission was
133 (21.2%). Local complications were diagnosed in 403 patients,
265 (42.2%) with acute peripancreatic fluid collection, and
138 (21.9%) with ANC. Necrosectomy was done in 32 (5.1%)
patients. Twenty-four patients died, all of them were from severe
AP group (24/131, 18.3%), leading to an overall mortality rate
of 3.8%.
Stratification by hematocrit
Baseline parameters. Patients in Group 3 (n = 162) or Group
2 (n = 114) were significantly younger (median 43 or 44 versus
46 years, both P < 0.05), had more males (82.1% versus 92.1%
versus 52.8%, all P < 0.05), higher body mass index (26.0 or
26.1 versus 24.4 kg/m2, both P < 0.001) compared with those in
Group 1 (n = 352). Group 3 had severe admission clinical
severity scores compared with those in Group 2 or Group 1 (sys-
temic inflammatory response syndrome, Glasgow, Acute Physiol-
ogy and Chronic Health Evaluation II and Sequential Organ
Failure Assessment scores, both P < 0.001; Table 1).
Clinical outcomes. After adjusting for both baseline variables
and admission clinical severity scores, Group 3 showed an
increased risk of developing POF (OR 2, 95% CI [1.1–3.8],
P = 0.03), while the incidence of mortality and ANC were simi-
lar when compared with Group 1 (both P > 0.1); there were no
significant differences in clinical outcomes between Group 2 and
Group 3 or 1 (all P > 0.15; Fig. 2a). As a result, Group 3 had
more actual severe cases than Group 2 or 1 (both P < 0.001),
while there was no significant difference between Group 2 and
Group 1 (Fig. 2b).
MLR and sensitivity analyses. In the MLR analyses, 7 (age,
Charlson comorbidity index, time to admission, body mass
Patients diagnosed with AP from 01/01/2016 to 08/30/2017: 4788
Patients excluded: 4160 
Symptom onset to admission > 48 hours: 1221
AP was not tprimary admitting diagnosis: 841
Age < 18 or > 70 years old: 934
Trauma, chronic pancreatitis, pancreatic cancer 
as etiologies or pregnancy: 600
Advanced co-morbidities: 219
Direct ICU admission or need ICU admission 
within 24 hours: 22
No hematocrit value at 24 hours: 269
Incomplete data: 54
Patients included in the study: 628
Admission hematocrit > 44%?
No Yes
Hematocrit at 24 hours > 44%? Rise in hematocrit at 24 hours
No
Group 1: 352
Yes
Group 2: 114 
No
Group 3: 162
Is there AP?
Yes
Is primary admission to ED?
To ward To ICU
Is there SIRS or organ failure?
Shock management Fluid therapy in ward
Fluid therapy in ED 
No
Yes
Noa Yes
No
a
b
Figure 1 Fluid management and patient inclusion flow chart. (a) Fluid management course of acute pancreatitis in West China hospital. (b) Patients
inclusion flow chart. AP, acute pancreatitis; ED, emergency department; ICU, intensive care unit; SIRS, systemic inflammatory response syndrome.
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index, referral, hemoconcentration, fluid rates of the first 24 h) of
9 independent covariables included in the model were signifi-
cantly associated with POF, 3 (body mass index, referral, fluid
rates of the first 24 h) of 9 independent covariables associated
with ANC, 5 (age, Charlson comorbidity index, body mass
index, hemoconcentration, fluid rates of the first 24 h) of 9 inde-
pendent covariables associated with mortality (Table 2). Hemo-
concentration on admission of general wards was significantly
associated with POF (OR 1.88, 95% CI [1.12–3.15], P = 0.016)
and mortality (4.02 [1.46–11.1], P = 0.007), but not ANC. The
fluid rates of the first 24 h was associated with POF (5.19
[3.55–7.59], P < 0.001), ANC (1.73 [1.34–2.23], P < 0.001) and
mortality (2.51 [1.68–3.73], P < 0.001).
When the analysis was restricted to patients (n = 271)
admitted ≤24 h after symptoms onset, the results were unchanged
from the overall patients except that the fluid rates of the first
24 h became just a trend toward increased ANC (1.48
[1.00–2.18], P = 0.05) (Table S2). Mortality was removed from
this subgroup analysis because there were only seven deaths.
When the analysis was restricted to patients (n = 292) who
admitted primarily (i.e. tertiary admissions removed), the results
were unchanged from the overall patients (Table S3). Mortality
was removed from this subgroup analysis because there were
only four deaths.
Fluid therapy rate and volume. The hematocrit level at
admission was the highest in Group 3 followed by Group 2 and
Group 1 (median 48% versus 45% versus 40%, all P < 0.001),
while at 24 h the hematocrit in the Group 2 was the highest and
followed by Group 3 and Group 1 (48% versus 43% versus
38%, all P < 0.001; Fig. 3a). The fluid therapy rate in the first
24 h was significantly faster in Group 3 compared with Group
2 (median 2.3 versus 2.1 mL/kg/h, P < 0.05) and Group
1 (median 2.3 versus 2.0 mL/kg/h, P < 0.05; Fig. 3b). Patients in
Group 3 also received a greater fluid volume over the first 24 h
compared with Group 2 or Group 1 (median 3875 versus 3450
versus 3200 mL, all P < 0.001; Fig. 3c).
Discussion
This study investigated the role of hemoconcentration in early
fluid therapy and clinical outcomes of AP patients in ward. The
considerable number of patients, especially the largest number of
severe AP patients of fluid therapy studies in this field so far, are
the strong points of our work. The key finding was that hem-
oconcentrated AP patients were more ill on admission, and clini-
cians tended to give them faster fluid rates and more fluid
volume in the first 24 h. Then these patients had increased risk of
POF even when after adjusting both baseline parameters and
admission clinical severity scores (predicted severity) than other
patients. MLR analyses confirmed that hemoconcentration on
admission and faster fluid rates in the first 24 h after admission
were significantly associated with POF and mortality, while only
the latter one was significantly associated with ANC. Given the
fact that early fluid rate was normally directly caused by severity
of AP and hematocrit level, our findings highlight the necessity of
Table 1 Baseline characteristics in patients stratified by hematocrit status during first 24 h of general ward admission
Parameters Group 1 (n = 352) Group 2 (n = 114) Group 3 (n = 162) P value*
Age, years† 46 (40, 53) 44 (35, 51) 43 (36, 49) 0.020‡
Gender, male, % 186 (52.8) 104 (91.2) 133 (82.1) 0.032§
Body mass index, kg/m2,† 24.4 (22.3, 27.0) 26.1 (24.0, 28.6) 26.0 (23.8, 28.0) <0.001‡
Charlson comorbidity index† 1 (0, 2) 2 (0, 2) 1 (0, 2) 0.108
Etiology
Biliary 90 (25.6) 25 (21.9) 31 (19.1) <0.001¶
Hypertriglyceridaemia 131 (37.2) 58 (50.9) 62 (38.3) 0.038††
Heavy alcohol use 26 (7.4) 7 (6.1) 16 (9.9) <0.001‡‡
Others 105 (29.8) 24 (21.1) 53 (32.7) <0.001‡‡
Time of ED to ward admission, hours† 6.5 (5.5, 8.0) 7.0 (5.5, 8.5) 6.0 (5.0, 9.0) 0.326
SIRS† 2 (1, 2) 1 (1, 3) 2 (1, 3) <0.001§§
Glasgow† 1 (0, 2) 1 (0, 2) 2 (1, 3) <0.001§§
APACHE II† 4 (2, 6) 4 (2, 6) 6 (3, 8) <0.001§§
SOFA† 0 (0, 1) 0 (0, 1) 0 (0, 2) 0.001§§
*Indicates χ2 (or Fisher’s exact test) for qualitive data and Kruskal–Wallis H test for quantitative data.
†Values are median (IQR).
‡P < 0.05, Group 1 versus Group 2 or Group 3.
§P < 0.05, between any two groups.
¶P < 0.05, Group1 versus Group 2.
††P < 0.05, Group 2 versus Group 1 or Group 3.
‡‡P < 0.05, Group 2 versus Group 3.
§§P < 0.05, Group 3 versus Group 1 or Group 2.
Group 1: hematocrit <44% on admission and < 44% at 24 h; Group 2: hematocrit increased and > 44% at 24 h; Group 3: hematocrit >44% on
admission and decreased thereafter during first 24 h.
APACHE II, acute physiology and chronic health evaluation II; ED, emergency department; SIRS, systemic inflammatory response syndrome; SOFA,
sequential organ failure assessment.
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conducting randomized trials to compare standardized early fast
and slow fluid therapy approaches for AP.
The rationale for fast fluid therapy in hemoconcentrated
patients is straightforward. Because hemoconcentration increases
viscosity and flow resistance,19 it is thought that hemodilution by
fast fluid therapy will improve flow and tissue oxygenation and
therefore clinical outcomes of AP.10,12 However, the oxygen car-
rying capacity of the blood is reduced during hemodilution,
although there are compensatory mechanisms to ensure normal
oxygen delivery, including an increase in cardiac output and tissue
oxygen extraction.19 There is a limit to these compensatory mecha-
nisms in extreme hemodilution.19 Furthermore, experimental studies
suggest that rapid hemodilution can worsen outcomes by decreasing
microcirculatory perfusion and increasing expression of inflamma-
tion and endothelial activation.20 Therefore, both early hemo-
concentration and rapid hemodilution are likely to contribute to
more severe disease.
There have been no previous studies that have explored
the association of hemoconcentration of general ward admission
and early fluid therapy with clinical outcomes in AP patients.
When stratified according to the changes of hematocrit during
the first 24 h, patients in Group 3 had the highest hematocrit
level and severe admission clinical severity scores than Group
2 and Group 1, so faster fluid rate and more fluid volume in the
first 24 h were given. Then, there was a significantly increased
risk of POF in Group 3 compared with those in Group 1 while
there was no significant difference between Group 2 and Group
3 and Group 1. The phenomenon still existed when after
adjusting both baseline parameters and admission clinical sever-
ity scores. Due to retrospective nature of data for fluid manage-
ment, it cannot be confirmed whether the worse clinical
outcomes of Group 3 was natural process of disease itself, or
early fast fluid therapy might exacerbate the process.
In our study, 64% of patients with severe AP had POF onset
during the first 24 h of admission to general wards (about 6.5 h
since ED admission). This finding was consistent with a recently
published study that investigated the timing of POF and found that
its onset occurred early during the disease course in most patients.16
Respiratory failure is the most common POF in patients with severe
AP.16 While rapid and high-volume fluid therapy will increase the
risk of pulmonary edema and exacerbate the respiratory failure.8,21,22
Thus, when AP has already combined with respiratory dysfunction,
it has to consider a restricted fluid therapy regimen,23,24 and the
statement “not all patients require or benefit from “aggressive” fluid
resuscitation, (and) calls into question previously held belief that
“more is better” may be the ideology.25
MLR analyses confirmed hemoconcentration and early
faster fluid rate were both significantly associated with POF, and
the latter was significantly associated with ANC. The tendency
of the cognition that early fast fluid therapy may be associated
with worse clinical outcomes is consistent with the prospective
study by Mao et al.26,27 in which rapid expansion and hemodilu-
tion was accompanied by increased incidence of sepsis and death
in patients with predicted severe AP who were directly admitted
to ICU. However, the cognition is contradictory with other recent
prospective studies in which primarily admitted patients who
were without systemic inflammatory response syndrome and
organ failure and were directly managed in the ED.7,9,28 These
controversies highlight that the effect of early fast fluid therapy
would be different in patients with different severity and in dif-
ferent disease course. Our study raised an important question for
fluid therapy in AP that is how the timing of “early” is defined?
Our recent work29,30 has shown that patients (admitted ≤36 h
0 1 2 3 4 5
POF OR (95% CI)
0 0.5 1 1.5 2 2.5
Acute Necrotic Collection
OR (95% CI)
0 5 10 15
Mortality OR (95% CI)
Multivariable Adjusted (P for Trend) 
Group 1: Reference
Group 2: 1.8 (0.8, 3.8) 
Group 3: 2.0 (1.1, 3.8) 
Group 1: Reference
Group 2: 1.3 (0.7, 2.3) 
Group 3: 1.1 (0.7, 1.8) 
Group 1: Reference
Group 2: 1.6 (0.2, 11) 
Group 3: 2.2 (0.6, 7.2) 
a
b
Figure 2 Features of patients stratified by hematocrit status during
the first 24 h of admission to general awards. (a) Trend analysis for clin-
ical outcomes after adjusting for both baseline variables and admission
clinical severity scores. (b) Severity classification. Group 1:
Hematocrit < 44% both on admission and at 24 h; group 2: Regardless
of admission level, hematocrit increased and > 44% at 24 h; group 3:
Hematocrit > 44% on admission and decreased thereafter during first
24 h. CI, confidence interval; MAP, mild acute pancreatitis;
MSAP, moderately severe acute pancreatitis; OR, odds ratio; POF, per-
sistent organ failure; SAP, severe acute pancreatitis.
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after symptom onset) may benefit from early fast fluid therapy
within the first 2 h of recruitment, but 6–8 h after recruitment
can increase the risk of POF and mortality, indicating a narrow
window for “very early” aggressive fluid therapy, and early rapid
fluid therapy is associated with increased rate of noninvasive
positive-pressure ventilation in hemoconcentrated patients with
severe AP. It is advisable for future studies to use timing of pain
onset to enrolment to define “very early” and “early” for fluid
therapy in AP, but the clear cut-off for these two time frames
needs to be developed.
Our study has several limitations. Practice variability is eval-
uated in a single center; the results may not therefore be representa-
tive. We lacked data on pre-ward fluid rate and volume. One of our
findings are indicative of a contribution of early faster fluid rate,
after adjusting for both baseline variables and predicted severity, but
owing to the retrospective observational design of the study, it is
Table 2 Multivariate analyses for persistent organ failure, acute necrotic collection, and mortality in all patients
Persistent organ failure Acute necrotic collection Mortality
Confounders Estimate P value Estimate P value Estimate P value
Age, year† 1.03 (1.01, 1.06) 0.008 1.00 (0.98, 1.02) 0.745 1.05 (1.00, 1.10) 0.042
Gender 0.84 (0.51, 1.41) 0.514 1.07 (0.68, 1.70) 0.771 0.49 (0.18, 1.33) 0.161
Charlson comorbidity index† 0.85 (0.70, 1.02) 0.084 0.91 (0.77, 1.07) 0.253 0.58 (0.37, 0.91) 0.016
Time to admission, hour† 1.03 (1.01, 1.05) 0.008 1.00 (0.98, 1.02) 0.962 1.03 (0.99, 1.07) 0.179
Body mass index, kg/m2,† 1.09 (1.04, 1.17) 0.002 1.04 (0.98, 1.09) 0.198 1.19 (1.06, 1.33) 0.002
Etiology 0.85 (0.71, 1.03) 0.096 0.88 (0.75, 1.04) 0.138 0.99 (0.69, 1.43) 0.962
Referral 3.64 (2.15, 6.16) <0.001 2.65 (1.70, 4.12) <0.001 2.81 (0.88, 9.00) 0.082
Hemoconcentration 2.49 (1.57, 3.96) <0.001 1.41 (0.93, 2.14) 0.101 4.36 (1.68, 11.4) 0.003
Fluid rate of first the 24 h 3.12 (1.99, 4.90) <0.001 1.35 (0.90, 2.04) 0.152 3.27 (1.32, 8.11) 0.010
†Continuous variable.
Age, gender (male versus female), Charlson comorbidity index, time to admission, body mass index, etiology (hypertriglyceridemia, biliary, alcoholic,
others), referral (yes versus no), hemoconcentration (yes, hematocrit >44% versus no, ≤44%), fluid rate of the first 24 h were included in multivari-
ate logistic regression analysis.
Figure 3 Fluid rates and volume of patients stratified by hematocrit status during the first 24 h of admission to ward. (a) Hematocrit change on admis-
sion and 24 h. (b) Comparison of fluid rates during the first 24 h between 3 groups. (c) Comparison of fluid volume during the first 24 h between three
groups. Group 1: Hematocrit < 44% both on admission and at 24 h; group 2: Regardless of admission level, hematocrit increased and > 44% at 24 h;
group 3: Hematocrit > 44% on admission and decreased thereafter during first 24 h. *P < 0.05 versus group 1; #P < 0.05 versus group 2.
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difficult to gain any conclusions about whether early fast fluid ther-
apy is harmful or beneficial in these AP patients. Therefore, the
original intention of the study is to highlight the necessity of con-
ducting randomized trials to compare standardized early fast and
slow fluid therapy strategies for AP. Finally, our cohort contained
high proportion of hyperlipidemia etiology (40%), much higher than
Western population but consistent with our recent publications15,16
and national trend.31
Conclusions
In conclusion, this study found that in AP patients who are
admitted in general wards after initial fluid therapy, hemo-
concentration is associated with faster fluid rate and an increased
risk of POF. However, whether early fluid therapy is harmful or
beneficial to these patients needs to be confirmed in randomized
trials that compare standardized early fast and slow fluid therapy.
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